arrow
S

Sara Pusceddu

enets center of excellence
H指数:34
被引数:3,539

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Bone metastases from neuroendocrine neoplasms: Results of an Italian nationwide survey of natural history and management

神经内分泌肿瘤骨转移:一项关于自然史和管理的意大利全国性调查结果

2025-11-180
OAAI
Clinical practice guidelines for the management of non-functioning advanced GEP-NENs: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology (AIOM) in collaboration with the Italian Association for Neuroendocrine Tumors (ITANET)

非功能性晚期GEP-NENs的管理临床实践指南:意大利医学肿瘤学会(AIOM)与意大利神经内分泌肿瘤学会(ITANET)合作,采用GRADE方法进行证据评估和推荐。

2025-11-120
OAAI
Digital Immunophenotyping of Lung Atypical Carcinoids and Large Cell Neuroendocrine Carcinomas Identifies Three Subtypes With Specific Tumor-Immune Microenvironment Features

肺不典型类癌和大细胞神经内分泌癌的数字免疫分型识别出具有特定肿瘤-免疫微环境特征的三个亚型

2025-10-240
OA
Design and rationale of the phase II PANDORA trial: first line chemo-immunotherapy in advanced Merkel cell carcinoma

II期PANDORA试验的设计与原理:晚期默克尔细胞癌的一线化疗免疫疗法

2025-06-120
OA
Oncocytic and spindle cell typical carcinoids of lung: different immunophenotype and biological behavior
2025-03-010
OAAI
The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) patients treated with [177Lu]Lu-DOTATATE
2024-09-052
PRE
Adverse skeletal related events in patients with bone-metastatic pheochromocytoma/paraganglioma
2024-09-012
PRE
Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: The phase 2 non-randomized SUTNET clinical trial
2024-09-010
PRE
A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas
2024-09-012
OAAI
Sequencing Treatments in Patients with Advanced Well-Differentiated Pancreatic Neuroendocrine Tumor (pNET): Results from a Large Multicenter Italian Cohort
2024-04-034
OAAI
Epidemiology of gastroenteropancreatic neuroendocrine neoplasms: a review and protocol presentation for bridging tumor registry data with the Italian association for neuroendocrine tumors (Itanet) national database
2024-01-043
OAAI
Characterization of two transcriptomic subtypes of marker-null large cell carcinoma of the lung suggests different origin and potential new therapeutic perspectives

标记无效的肺大细胞癌的两种转录组亚型的表征表明不同的起源和潜在的新治疗观点

2024-01-030
OAAI
Safety and antitumor activity of metformin plus lanreotide in patients with advanced gastro-intestinal or lung neuroendocrine tumors: the phase Ib trial MetNET2

二甲双胍联合兰瑞肽治疗晚期胃肠道或肺神经内分泌肿瘤的安全性和抗肿瘤活性: Ib期试验MetNET2

2023-12-140
OAAI
Gender-related differences in patients with carcinoid syndrome: new insights from an Italian multicenter cohort study
2023-10-145
OAAI
Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial

评估卡博替尼联合兰瑞肽在胃肠胰腺和胸部神经内分泌肿瘤中的安全性和活性: II期LOLA试验的原理和方案

2023-09-266
OAAI